Brinson Patrick Starts MannKind (MNKD) at Market Outperform
Tweet
Share
E-mailGet Alerts MNKD Hot Sheet
Price: $3.91 -4.87%
Rating Summary:
13 Buy, 2 Hold, 6 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 24 | New: 9
Rating Summary:
13 Buy, 2 Hold, 6 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 14 | Down: 24 | New: 9
Join SI Premium – FREE
Brinson Patrick initiates coverage on MannKind (NASDAQ: MNKD) with a Market Outperform. PT $6.00.
The analyst comments, "MannKind Corporation's rapid-acting insulin, Afrezza, is currently in two Phase 3 pivotal trials with their handheld drug delivery device called Dreamboat. We believe the two Complete Response letters they received with their previous device has created a buying opportunity for investors today. Following a completion of a financing that carries them through 2013, we recommend investors begin accumulating MNKD shares."
With a $33 billion worldwide branded diabetes market opportunity and the increasing pressures on major pharma's in the diabetes segment, Brinson Patrick's analyst believes Afrezza is in position to reach $1 billion in 2016 US revenues.
The $6.00 price target based on the mean value of their 2014 to 2018 EPS target.
For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.
Shares of MannKind closed at $2.13 yesterday.
The analyst comments, "MannKind Corporation's rapid-acting insulin, Afrezza, is currently in two Phase 3 pivotal trials with their handheld drug delivery device called Dreamboat. We believe the two Complete Response letters they received with their previous device has created a buying opportunity for investors today. Following a completion of a financing that carries them through 2013, we recommend investors begin accumulating MNKD shares."
With a $33 billion worldwide branded diabetes market opportunity and the increasing pressures on major pharma's in the diabetes segment, Brinson Patrick's analyst believes Afrezza is in position to reach $1 billion in 2016 US revenues.
The $6.00 price target based on the mean value of their 2014 to 2018 EPS target.
For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here.
Shares of MannKind closed at $2.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
- Raymond James Starts Faeth Therapeutics (FTH) at Outperform
- Cantor Fitzgerald Starts Duos Technologies Group (DUOT) at Overweight, 'Under The Radar AI Data Center Play'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
